{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:21:09Z","timestamp":1758817269257},"reference-count":72,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,12]],"date-time":"2006-07-12T00:00:00Z","timestamp":1152662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J of Med Genetics Pt C"],"published-print":{"date-parts":[[2006,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematologic abnormalities are common in individuals with Down syndrome (DS). Increased erythrocyte mean corpuscular volume (MCV) is frequently found among DS infants and remains elevated throughout life in two\u2010thirds of patients, making interpretation of red cell indices for diagnosis of nutritional anemias or bone marrow failure disorders more challenging. Transient myeloproliferative disorder (TMD) associated with pancytopenia, hepatosplenomegaly, and circulating immature WBCs, is found almost exclusively in DS infants with an incidence of approximately 10%. In most cases, TMD regresses spontaneously within the first 3 months of life, but in some children, it can be life threatening or even fatal. Despite the high rate of spontaneous regression, TMD can be a preleukemic disorder in 20\u201330% of children with DS. The types of malignancy, response to therapy, and clinical outcome in children with DS are also unique. There is an increased risk of leukemia with an equal incidence of lymphoid and myeloid leukemia. Acute megakaryocytic leukemia (AMKL) subtype is the most common form of acute myeloid leukemia (AML) in this setting, and is uncommon in children without DS. Somatic mutations of the gene encoding the hematopoetic growth factor<jats:italic>GATA1<\/jats:italic>have been shown to be specific for TMD and AMKL in children with DS. Myelodysplastic syndrome can precede AML. Children with DS and leukemia are more sensitive to some chemotherapeutic agents such as methotrexate than other children which requires careful monitoring for toxicity. Although the risk for leukemia is higher in individuals with DS, these patients have a lower risk of developing solid tumors, with the exception of germ cell tumors, and perhaps retinoblastoma and lymphoma. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajmg.c.30096","type":"journal-article","created":{"date-parts":[[2006,7,12]],"date-time":"2006-07-12T21:50:28Z","timestamp":1152741028000},"page":"149-157","source":"Crossref","is-referenced-by-count":28,"title":["Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome"],"prefix":"10.1002","volume":"142C","author":[{"given":"Natalia","family":"Dixon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherri","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,12]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3383"},{"key":"e_1_2_16_3_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.1988.03720060014018","article-title":"Macrocytosis and leukopenia in Down's syndrome","volume":"259","author":"Akin K","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200201000-00004"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.2.442"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199502000-00003"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(83)90092-0"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.23.020102.075739"},{"key":"e_1_2_16_9_1","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood.V93.5.1643","article-title":"Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation","volume":"93","author":"Belkov VM","year":"1999","journal-title":"Blood"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90429-0"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830050904"},{"key":"e_1_2_16_12_1","volume-title":"Immunodeficiency Diseases","author":"Burgio GR","year":"1983"},{"key":"e_1_2_16_13_1","first-page":"100","article-title":"Development of a clinic for adults with Down syndrome","volume":"32","author":"Chicoine B","year":"1994","journal-title":"Mental Retardation"},{"key":"e_1_2_16_14_1","first-page":"1","article-title":"Health Care guidelines for individuals with down syndromes","volume":"4","author":"Cohen WI","year":"1999","journal-title":"Down Syndr Q"},{"key":"e_1_2_16_15_1","first-page":"1677","article-title":"Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML\u2010BFM Study Group","volume":"10","author":"Creutzig U","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2004.11.002"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20066"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019609030827"},{"key":"e_1_2_16_19_1","volume-title":"A pilot study screening for the prevalence of iron deficiency in children and adolescents with Down syndrome","author":"Dixon NE","year":"2006"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1452-7"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20207"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.060"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(86)80047-6"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2456"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00435-6"},{"key":"e_1_2_16_26_1","first-page":"1569","article-title":"Childhood myelodysplastic syndrome in Denmark: Incidence and predisposing conditions","volume":"9","author":"Hasle H","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01645.x"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05264-2"},{"key":"e_1_2_16_29_1","first-page":"82","volume-title":"Caring for individuals with Down syndrome and their families: Report of the Third Ross Roundtable on Critical Issues in Family Medicine in collaboration with the Society of Teachers of Family Medicine","author":"Heaton CJ","year":"1995"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0013"},{"key":"e_1_2_16_31_1","first-page":"392","article-title":"Transient abnormal myelopoiesis of infancy associated with trisomy 21","volume":"15","author":"Homans AC","year":"1993","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1995.02170200114021"},{"key":"e_1_2_16_33_1","first-page":"84","article-title":"Hematological and biochemical studies in children with Down syndrome","volume":"33","author":"Ibarra B","year":"1990","journal-title":"Ann Genet"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1996.tb04318.x"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02027.x"},{"key":"e_1_2_16_36_1","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891","volume":"91","author":"Lange BJ","year":"1998","journal-title":"Blood"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400651"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(82)80428-9"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109053251004"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02616.x"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320160207"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/201317a0"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3904"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(65)92994-6"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80122-7"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21518"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.04.007"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1361"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3599"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/uog.87"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80119-5"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320460509"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12987-X"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7346.1155"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<929::AID-CNCR14>3.0.CO;2-Y"},{"key":"e_1_2_16_56_1","first-page":"448","article-title":"A lack of neuroblastoma in Down's syndrome: A study from 11 European countries","volume":"58","author":"Satg\u00e9 D","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.0.CO;2-M"},{"key":"e_1_2_16_58_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2788.1997.03838.x","article-title":"Early menopause in women with Down syndrome","volume":"41","author":"Schuypf N","year":"1996","journal-title":"J Intell Disabil Res"},{"key":"e_1_2_16_59_1","first-page":"1031","article-title":"Health care management of adults with Down syndrome","volume":"64","author":"Smith DS","year":"2001","journal-title":"Am Fam Physician"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0705.2001.00384.x"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81149-7"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20092"},{"key":"e_1_2_16_63_1","first-page":"1393","article-title":"Expression of chromosome 21\u2010localized genes in acute myeloid leukemia: Differences between Down syndrome and non\u2010Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin","volume":"94","author":"Taub JW","year":"1999","journal-title":"Blood"},{"key":"e_1_2_16_64_1","first-page":"417","article-title":"Macrocytosis in Down syndrome","volume":"95","author":"Wachtel TJ","year":"1991","journal-title":"Am J Ment Retard"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng955"},{"key":"e_1_2_16_66_1","first-page":"656","article-title":"Coagulation in cyanotic congenital heart disease","volume":"124","author":"Wedemeyer AL","year":"1972","journal-title":"Am J Dis Child"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1982.03970400028007"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3446"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1159\/000244089"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019209018329"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(94)90111-2"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0146-0005(97)80025-0"},{"key":"e_1_2_16_73_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0272-2712(18)30133-1","article-title":"Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome","volume":"19","author":"Zipursky A","year":"1999","journal-title":"Clin Lab Med"}],"container-title":["American Journal of Medical Genetics Part C: Seminars in Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajmg.c.30096","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajmg.c.30096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T08:25:35Z","timestamp":1707121535000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajmg.c.30096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,12]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8,15]]}},"alternative-id":["10.1002\/ajmg.c.30096"],"URL":"https:\/\/doi.org\/10.1002\/ajmg.c.30096","archive":["Portico"],"relation":{},"ISSN":["1552-4868","1552-4876"],"issn-type":[{"value":"1552-4868","type":"print"},{"value":"1552-4876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,12]]}}}